Estrogen is processed primarily in the liver. Where liver function is good, estrogens are broken down and excreted efficiently. Where it is compromised — by fatty liver, inflammation or nutritional deficiency — estrogen accumulates in circulation relative to progesterone.
That state is estrogen dominance, and it is linked to heavy periods, PMS, endometriosis, uterine fibroids, fibrocystic breasts, and a raised risk of estrogen-sensitive cancers. Because the liver sits upstream of all of this, hepatic health is one of the more directly modifiable levers in the whole picture, which is why it is the focus of the rest of this article.
What is estrogen dominance?
Estrogen dominance describes a relative imbalance: more estrogen in circulation than progesterone can offset, rather than an absolute overproduction of estrogen. It can occur alongside normal, low or even high estrogen levels, because what drives symptoms is the ratio between the two hormones, not either one in isolation. Progesterone naturally declines with anovulatory cycles, perimenopause and chronic stress, so estrogen can stay flat while progesterone falls and the ratio still shifts toward dominance.
The liver's role is why the same estrogen level produces symptoms in one person and none in another: clearance speed, not production, sets how long estrogen stays biologically active in the blood. Two people making identical amounts of estradiol can end up with very different circulating levels depending on how efficiently the liver conjugates and excretes it, which is what the rest of this article covers in detail.
There is no single blood test for estrogen dominance, since a snapshot of estradiol says nothing about the ratio to progesterone or how quickly the liver is clearing either one. In practice it is identified from the symptom pattern below, sometimes alongside cycle-timed hormone panels or a liver function check when a hepatic cause is suspected.
It is worth noting that estrogen dominance is a descriptive, clinically useful term rather than a single formal diagnosis: it describes a pattern that shows up across several distinct conditions, from PCOS to endometriosis to ordinary PMS, each with its own primary cause. That is also why the same liver-focused support strategies below tend to help across all of them, rather than one narrow group of people.
Symptoms of estrogen dominance
High estrogen symptoms and estrogen dominance symptoms overlap heavily, since both describe the same underlying hormonal ratio. The most commonly reported include:
Heavy, prolonged or clot-heavy periods, from a uterine lining built up by estrogen's proliferative effect and not fully opposed by progesterone
Pronounced PMS: irritability, anxiety or low mood in the week before a period, when the progesterone-to-estrogen ratio is at its lowest
Breast tenderness, swelling or fibrocystic lumps, since breast tissue is one of the most estrogen-responsive tissues in the body
Bloating and water retention, especially premenstrually
Weight gain concentrated around the hips, thighs and lower abdomen
Fatigue that doesn't track with how much sleep is actually being had
Headaches or migraines that cluster around ovulation or menstruation, when estrogen shifts fastest
Reduced libido
Hair thinning or shedding
Difficulty concentrating, often described as brain fog
Cold hands and feet
Sleep that is lighter or more broken in the days before a period
None of these is diagnostic on its own, and each is common to other conditions too. They are more useful read together as a pattern than checked off one at a time: several appearing at once, timed to the luteal phase of the cycle, is the pattern clinicians look for.
How the liver metabolises estrogen
Whatever raises estrogen exposure in the first place, whether xenoestrogens, stress, contraceptives or adipose tissue, the liver is what decides how much of it actually stays in circulation. Hepatic estrogen clearance runs in three stages.
Phase 1 — Hydroxylation. Liver CYP enzymes convert estradiol (E2) and estrone (E1) into hydroxylated intermediates. Which hydroxylated intermediate this step produces matters: the 2-hydroxy route is considered protective, while the 16-alpha and 4-hydroxy routes are more biologically active and, in the case of 4-hydroxy metabolites, potentially genotoxic if not promptly neutralised in Phase 2.
Phase 2 — Conjugation. Those hydroxylated metabolites are neutralised and made water-soluble by three routes: A bottleneck at any one of the three routes backs up the whole pathway, since methylation, glucuronidation and sulfation are not fully interchangeable: each handles a different share of the hydroxylated estrogens Phase 1 produces.
Methylation (the COMT enzyme, requiring SAMe and magnesium)
Glucuronidation (UGT enzymes) — the primary route for clearing estradiol
Sulfation (SULT enzymes)
Phase 3 — Gut excretion. Conjugated estrogens pass into bile and are eliminated in stool. Gut bacteria producing beta-glucuronidase, however, can deconjugate estrogen, allowing it to be reabsorbed into the bloodstream — a process called enterohepatic recirculation. How much is reabsorbed here depends heavily on gut transit time and the composition of the microbiome, which is why gut health features throughout the causes and support sections below.
How liver dysfunction disrupts estrogen balance
1. Reduced detoxification enzyme activity. NAFLD and liver inflammation lower both CYP enzyme activity and Phase 2 conjugation. In practice, that means a given dose of estradiol takes longer to clear, so its effects extend further into the next cycle instead of tapering off before it begins.
2. Low SHBG. Sex hormone-binding globulin is made exclusively in the liver, and it binds estrogen in circulation to keep it biologically inactive. Hepatic steatosis and insulin resistance reduce SHBG production, which raises free estradiol regardless of how much estrogen is actually being produced. Because SHBG also binds testosterone, falling levels raise free androgens at the same time as free estrogen, which is part of why estrogen dominance and androgen-driven symptoms like acne and excess hair growth often appear together in PCOS.
3. Gut dysbiosis and the estrobolome. The estrobolome is the set of gut bacteria capable of deconjugating estrogen. Dysbiosis — frequently accompanying liver disease — increases beta-glucuronidase activity, amplifying enterohepatic recirculation and raising overall estrogen exposure. Antibiotic use, a low-fibre diet and chronic constipation all shift the gut microbiome toward higher beta-glucuronidase output, so the same liver output of conjugated estrogen still results in more of it circulating.
4. Aromatase upregulation. Chronic liver inflammation elevates TNF-α and IL-6, which upregulate aromatase, the enzyme converting androgens into estrogens in adipose tissue. In metabolic disease, visceral fat becomes a significant source of estrogen. This creates a feedback loop: more visceral fat makes more estrogen, and estrogen dominance itself promotes further fat storage in the same tissue, which is why the pattern tends to worsen over time rather than plateau on its own.
5. Impaired COMT methylation. COMT inactivates potentially harmful catechol estrogen intermediates, a process requiring SAMe, folate, B12 and magnesium — all of which are depleted in liver disease. As COMT activity falls, reactive intermediates with genotoxic potential accumulate. Slower COMT variants are common, and combined with nutrient depletion they compound the problem further. Testing for the variant isn't necessary to act on it, since the same methylation-support nutrients help regardless of genotype.
Common causes of estrogen dominance beyond the liver
Liver function decides how much estrogen accumulates once it is in circulation, but several everyday exposures and life-stage changes raise the amount that has to be cleared in the first place:
Xenoestrogens. BPA and phthalates from plastics, and residues from certain pesticides, bind estrogen receptors and add to the body's overall estrogenic load, on top of whatever estrogen the body makes on its own. Plastic food containers, canned-food linings and heavily sprayed produce are the largest everyday sources, and cutting back on them is a low-effort way to lower the overall load the liver has to clear.
Chronic stress. Cortisol and progesterone are both made from the same precursor, pregnenolone. Under sustained stress, the body prioritises cortisol production, a shift sometimes called pregnenolone steal, leaving less progesterone available to balance estrogen. This is one reason estrogen dominance so often appears alongside stress-related sleep and mood symptoms rather than in isolation.
Hormonal contraceptives. Combined oral contraceptives and other synthetic-estrogen methods raise circulating estrogen directly, an effect layered on top of whatever the liver is already managing. This is not a reason to avoid them, but it is a reason to expect a higher baseline clearance demand on the liver while using one.
Excess body fat. Adipose tissue produces its own estrogen via aromatase, so higher body fat, particularly visceral fat, raises total estrogen production independent of ovarian output, compounding whatever the liver is already clearing.
The perimenopausal transition. Progesterone falls earlier and faster than estrogen through perimenopause, so the ratio between them shifts toward dominance for years before menopause itself. It is also why the same support strategies that help earlier estrogen dominance, listed below, are frequently recommended through perimenopause specifically.
Chronic constipation. Slower bowel transit gives gut bacteria more time to deconjugate excreted estrogen before it leaves the body, increasing reabsorption independent of the bacterial composition described above.
Health conditions linked to estrogen dominance
Whatever combination of the causes above produced it, estrogen dominance is associated with:
Heavy or irregular menstrual bleeding driven by higher estrogen relative to progesterone thickening the uterine lining more than usual.
PMS and PMDD luteal-phase symptoms that track with a lower progesterone-to-estrogen ratio in the second half of the cycle.
Endometriosis estrogen promotes growth of endometrial-like tissue outside the uterus, so higher circulating levels are associated with more extensive disease.
Uterine fibroids fibroid tissue carries more estrogen and progesterone receptors than normal uterine muscle, making fibroids estrogen-responsive and prone to growth under sustained dominance.
PCOS (which commonly co-exists with NAFLD) shares the same low-SHBG, high-insulin pattern described above.
Fibrocystic breast changes breast tissue is highly estrogen-responsive, and cyclical swelling or tenderness tracks with the luteal-phase estrogen-to-progesterone ratio.
Worsening insulin resistance and metabolic dysfunction estrogen dominance and insulin resistance reinforce each other through the SHBG and aromatase pathways described above.
Evidence-based support strategies
The evidence on how to flush out excess estrogen does not point to a single estrogen detox, it points to supporting each stage of clearance the liver and gut already perform:
Cruciferous vegetables / I3C / DIM — modulate Phase 1 detoxification, shifting estrogen metabolism toward the protective 2-hydroxy pathway.
Methylation cofactors. Supporting COMT activity requires adequate folate (as 5-MTHF), methylcobalamin (B12), magnesium and betaine — all frequently depleted in liver disease and in estrogen-dominant conditions alike.
Reducing enterohepatic recirculation. Calcium D-glucarate inhibits intestinal beta-glucuronidase, cutting estrogen reabsorption. Dietary fibre binds conjugated estrogens in the gut and increases faecal excretion. Regular bowel transit is essential here — constipation directly increases estrogen reabsorption. This is one of the more directly actionable levers described in this article, since it targets Phase 3 regardless of how well Phase 1 and Phase 2 are running.
Fibre and lignans. Flaxseed lignans and soluble fibre both bind estrogen metabolites in the gut before they can be reabsorbed, working alongside calcium D-glucarate rather than replacing it.
Limiting alcohol. Alcohol impairs Phase 1 and Phase 2 detoxification, depletes NAD⁺ and upregulates adipose aromatase. Dose-dependent increases in circulating estradiol and estrone have been documented at even moderate levels of consumption. This matters more for estrogen dominance specifically than a general everything in moderation framing would suggest, since alcohol works against Phase 1, Phase 2 and adipose aromatase all at the same time.
Insulin management. Elevated insulin suppresses SHBG transcription and activates aromatase. Low-glycaemic diets, fewer refined carbohydrates and more fibre all raise SHBG and lower free estradiol. This is also why estrogen dominance and insulin resistance are so often found together clinically rather than as separate, unrelated issues.
Sleep and stress management. Poor sleep and chronic stress raise cortisol at progesterone's expense through the pregnenolone-steal mechanism described above, so consistent sleep and stress-reduction practices support the hormone ratio directly, not just the liver's clearance capacity.
Reducing xenoestrogen exposure. Swapping plastic food containers for glass, cutting back on canned and heavily processed foods, and choosing produce with lower pesticide residue all lower the estrogenic load the liver and gut have to process in the first place.
Liver-supportive compounds: used alongside the diet and lifestyle changes above rather than instead of them.
Silymarin (milk thistle) — protects hepatocytes and supports overall liver detoxification capacity, including Phase 2 conjugation and biliary excretion. Clinical use for liver support spans decades, and it is generally well tolerated at typical doses.
N-acetyl cysteine (NAC) — replenishes hepatic glutathione, essential to Phase 2 detoxification. Glutathione is also the liver's main defence against the reactive intermediates Phase 1 can generate, so replenishing it supports Phase 2 and general hepatic resilience together.
Artichoke leaf extract — stimulates bile flow, the primary excretion route for conjugated estrogens. Better bile flow also supports fat digestion and the gut environment more broadly, which is part of why it is frequently paired with milk thistle rather than used alone.
Exercise. Regular physical activity reduces visceral adiposity, aromatase activity and liver fat. Both aerobic and resistance training significantly reduce hepatic triglycerides in NAFLD. The effect is partly independent of weight loss: even modest activity lowers circulating insulin and inflammatory signalling, both of which feed into the aromatase and SHBG pathways described earlier.
The strategies above map onto specific points in the clearance pathway. As a quick reference:
Strategy | What it targets |
|---|---|
Cruciferous vegetables / I3C / DIM | Phase 1: shifts hydroxylation toward the protective 2-hydroxy route |
Methylation cofactors (folate, B12, magnesium, betaine) | Phase 2: supports COMT methylation |
Calcium D-glucarate, dietary fibre, flaxseed lignans | Phase 3: reduces enterohepatic recirculation in the gut |
Limiting alcohol | Phase 1 and Phase 2 capacity, plus adipose aromatase |
Low-glycaemic diet, insulin management | SHBG production and aromatase activity |
Silymarin, NAC, artichoke leaf extract | Overall hepatocyte support, glutathione and bile flow |
Sleep and stress management | Progesterone availability via the pregnenolone-steal pathway |
Exercise | Visceral fat, insulin and inflammatory signalling |
Reducing xenoestrogen exposure | Overall estrogenic load entering the body |
Estrogen dominance is rarely a single-cause problem. It sits at the intersection of how much estrogen the body is exposed to, how well the liver clears it, and how much progesterone is available to balance it, which is why the strategies that help most tend to work on several of those points at once rather than any single one. Persistent or severe symptoms, especially very heavy bleeding, are worth raising with a clinician rather than managing through diet and supplements alone, since several of the conditions linked to estrogen dominance above need their own direct treatment.
References
Cited by the original article:
Abenavoli L, et al. Phytother Res. 2010;24(10):1423–1432.
Aubertin-Leheudre M, Adlercreutz H. Br J Nutr. 2009.
Barbagallo M, Dominguez LJ. World J Diabetes. 2015;6(10):1152–1157.
Bertone-Johnson ER, et al. Arch Womens Ment Health. 2017;20(6):733–741.
Bulun SE. N Engl J Med. 2009;360(3):268–279.
Bulun SE, et al. Endocrinol Metab Clin North Am. 2021;50(1):125–139.
Bulun SE, et al. Pharmacol Rev. 2005;57(3):359–383.
Buzzard LM, et al. Clin Endocrinol (Oxf). 2020;93(3):235–249.
Cavalieri E, Rogan E. J Steroid Biochem Mol Biol. 2011;125(3–5):169–180.
Ding EL, et al. N Engl J Med. 2009;361(12):1152–1163.
Dorgan JF, et al. Serum hormones and the alcohol–breast cancer association in postmenopausal women. J Natl Cancer Inst. 2001.
Guillemette C. Pharmacogenomics J. 2003;3(3):136–158.
Keating SE, et al. J Hepatol. 2012;57(1):157–166.
Kwa M, et al. J Natl Cancer Inst. 2016;108(8):djw029.
Lonardo A, et al. Hepatology. 2019;70(4):1457–1469.
Mauvais-Jarvis F, et al. Endocr Rev. 2013;34(3):309–338.
Melse-Boonstra A. Front Nutr. 2020;7:101.
Merrell MD, Cherrington NJ. Drug Metab Rev. 2011;43(3):317–334.
Mokhtari V, et al. Cell J. 2017;19(1):11–17.
Palmery M, et al. Eur Rev Med Pharmacol Sci. 2013;17(13):1804–1813.
Plottel CS, Blaser MJ. Cell Host Microbe. 2011;10(4):324–335.
Reed MJ, et al. Endocr Rev. 2005;26(2):171–202.
Simpson ER. J Steroid Biochem Mol Biol. 2003;86(3–5):225–230.
Thomson CA, et al. Nutr Rev. 2016;74(7):432–443.
Vargas-Mendoza N, et al. World J Hepatol. 2014;6(3):144–149.
Wallace IR, et al. Clin Endocrinol. 2013;78(3):321–329.
